Adage Capital Partners
KDNY

Adage Capital Partners’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Adage Capital Partners’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-134,110
Closed -$5.15M – 976
2023
Q2 		$5.15M Sell
134,110
-1,569,890
-92% -$40.3M 0.01% 667
2023
Q1 		$39.4M Buy
1,704,000
+883,822
+108% +$21.1M 0.09% 264
2022
Q4 		$21.5M Buy
820,178
+720,178
+720% +$16M 0.05% 400
2022
Q3 		$1.97M Sell
100,000
-50,000
-33% -$1M ﹤0.01% 856
2022
Q2 		$2.62M Buy
+150,000
New +$2.35M 0.01% 864

Adage Capital Partners's KDNY Position: Q3 2023 in Review

Adage Capital Partners sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 134,110 shares — an estimated $5.15M sold.

Adage Capital Partners first reported a position in KDNY in Q2 2022 and held it in 5 quarters. The position peaked at $39.4M in Q1 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.

  • Adage Capital Partners reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Adage Capital Partners sold 134,110 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $5.15M.
  • Adage Capital Partners first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2022 and held it in 5 quarters.
  • Adage Capital Partners's Chinook Therapeutics, Inc. Common Stock position peaked at $39.4M in Q1 2023.
  • 2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Adage Capital Partners's 13F filing for Q3 2023, filed 14 Nov 2023.